Form 4 for CGTX COGNITION THERAPEUTICS INC
Accepted 2025-09-23 00:00:00 ET · period of report 2025-09-19 · accession 0001104659-25-092671 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-23 | 2025-09-19 | CGTX | Fletcher Aaron G.L. | Dir, 10% | M - OptEx | $0.84 | +7,729 | 56.2K | +16% | +$6,492 |
| D | 2025-09-23 | 2025-09-19 | CGTX | Fletcher Aaron G.L. | Dir, 10% | M - OptEx | $0.00 | -7,729 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-19 | M | A | 7,729 | $0.84 | 56,229 | D | — | — | (F1) Of the 56,229 shares reported as held directly by Aaron G.L. Fletcher ("Dr. Fletcher"), 7,729 shares, are held for the benefit of Dr. Fletcher and 48,500 shares, 34,000 of which represent restricted stock units, are held for the benefit of BP Directors, LP ("Bios Directors" and such securities the "Bios Directors Securities") under an agreement with Bios Directors pursuant to which Dr. Fletcher agreed that he will hold the Bios Directors Securities merely as a nominee for Bios Directors. (F2) Bios Directors may be deemed the direct or indirect beneficial owner of the Bios Directors Securities, and Bios Equity Partners, LP ("Bios Equity I"), Cavu Management, LP ("Cavu Management"), Bios Capital Management, LP ("Bios Management"), Cavu Advisors LLC ("Cavu Advisors"), Bios Advisors GP, LLC ("Bios Advisors"), Leslie W. Kreis, Jr. ("Mr. Kreis") and Dr. Fletcher may each be deemed the indirect beneficial owner of the Bios Directors Securities through his or its respective indirect interest in Bios Directors. |
| 2 | Derivative | Stock Option (right to buy) | 2025-09-19 | M | D | 7,729 | $0.00 | 0 | D | $0.84 · — to 2025-09-22 | 7,729 Common Stock | (F8) The option was written and fully vested before the reporting persons became Section 16 insiders of the Issuer and therefore was reported on the reporting persons' Form 3 filed on October 7, 2021. |